Assessing the Pathophysiology of Hyperglycemia in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium

Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)

doi:10.1097/mpa.0000000000002074

Assessing the Pathophysiology of Hyperglycemia in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium

Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)

Pediatric Endocrinology

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Objectives The metabolic abnormalities that lead to diabetes mellitus (DM) after an episode of acute pancreatitis (AP) have not been extensively studied. This article describes the objectives, hypotheses, and methods of mechanistic studies of glucose metabolism that comprise secondary outcomes of the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study. Methods Three months after an index episode of AP, participants without preexisting DM will undergo baseline testing with an oral glucose tolerance test. Participants will be followed longitudinally in three subcohorts with distinct metabolic tests. In the first and largest subcohort, oral glucose tolerance tests will be repeated 12 months after AP and annually to assess changes in β-cell function, insulin secretion, and insulin sensitivity. In the second, mixed meal tolerance tests will be performed at 3 and 12 months, then annually, and following incident DM to assess incretin and pancreatic polypeptide responses. In the third, frequently sampled intravenous glucose tolerance tests will be performed at 3 months and 12 months to assess the first-phase insulin response and more precisely measure β-cell function and insulin sensitivity. Conclusions The DREAM study will comprehensively assess the metabolic and endocrine changes that precede and lead to the development of DM after AP.

Original language	English (US)
Pages (from-to)	575-579
Number of pages	5
Journal	Pancreas
Volume	51
Issue number	6
DOIs	https://doi.org/10.1097/mpa.0000000000002074
State	Published - Jul 1 2022

Bibliographical note

Funding Information:
K.M.D. has declared research support from Sanofi, Viacyte, Abbott, and Dexcom; consulting activities with Eli Lilly, Boehringer Ingelheim, Elsevier, and Dexcom; and honoraria from UptoDate, Medscape, Academy for Continued Healthcare Learning, and Cardiometabolic Health Congress. M.D.B. has declared research support from Viacyte and Dexcom and consulting activities with Insulet (advisory board). C.E.-M. has received research support from Lilly, Astellas Pharma, Bristol Myers Squibb, and Nimbus Therapeutics and consulting/advisory fees from Avotres, Inc, DiogenX, Isla Technologies, Provention Bio, Inc, MaiCell Therapeutics, and Dompe. R.E.P. has received grants (directed to his institution) from Hanmi Pharmaceutical Co, Ltd, Janssen, Metavention, Novo Nordisk, Poxel SA, and Sanofi; has received consulting fees (directed to his institution) from AstraZeneca, Corcept Therapeutics Incorporated, Glytec LLC, Hanmi Pharmaceutical Co, Ltd, Janssen, Merck & Co, Inc., Mundipharma, Novo Nordisk, Pfizer, Inc, Sanofi, Scohia Pharma, Inc, and Sun Pharmaceutical Industries; and has received support for attending meetings/travel (directed to his institution or to the travel provider) from AstraZeneca, Glytec LLC, Merck & Co, Inc, Mundipharma, Novo Nordisk, and Pfizer, Inc. E.K.S. has received honoraria from Medscape. C.S. has participated on an advisory board for Vertex Pharmaceuticals. F.G.S.T. has declared research support from Dompé Pharmaceuticals and previous consulting activities with Sanofi, Eli Lilly, and AstraZeneca. The other authors declare no conflict of interest.

Funding Information:
The T1DAP Consortium is funded by the National Institute of Diabetes and Digestive and Kidney Diseases: grants U01DK127384, U01DK127367, U01DK127377, U01DK127392, U01DK127382, U01DK127403, U01DK127404, U01DK127388, U01DK127395, U01DK127378, and U01DK127400. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.

Keywords

AIRg - acute insulin response to glucose
AP - acute pancreatitis
AUC - area under the curve
DM - diabetes mellitus
DREAM - Diabetes Related to Acute Pancreatitis and its Mechanisms
FSIGTT - frequently sampled intravenous glucose tolerance test
GIP - glucose-dependent insulinotropic polypeptide
GLP-1 - glucagon-like peptide 1
HOMA-IR - homeostasis model assessment-insulin resistance
MMTT - mixed meal tolerance test
OGTT - oral glucose tolerance test
PP - pancreatic polypeptide
frequently sampled intravenous glucose tolerance test
islet
mixed-meal tolerance test
pancreatogenic diabetes
type 3c diabetes mellitus
β-cell function

PubMed: MeSH publication types

Journal Article
Research Support, N.I.H., Extramural

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1097/mpa.0000000000002074

Find It

Find It at U of M Libraries

Cite this

@article{08af1c769e604bd097605e208397fe25,

title = "Assessing the Pathophysiology of Hyperglycemia in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium",

abstract = "Objectives The metabolic abnormalities that lead to diabetes mellitus (DM) after an episode of acute pancreatitis (AP) have not been extensively studied. This article describes the objectives, hypotheses, and methods of mechanistic studies of glucose metabolism that comprise secondary outcomes of the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study. Methods Three months after an index episode of AP, participants without preexisting DM will undergo baseline testing with an oral glucose tolerance test. Participants will be followed longitudinally in three subcohorts with distinct metabolic tests. In the first and largest subcohort, oral glucose tolerance tests will be repeated 12 months after AP and annually to assess changes in β-cell function, insulin secretion, and insulin sensitivity. In the second, mixed meal tolerance tests will be performed at 3 and 12 months, then annually, and following incident DM to assess incretin and pancreatic polypeptide responses. In the third, frequently sampled intravenous glucose tolerance tests will be performed at 3 months and 12 months to assess the first-phase insulin response and more precisely measure β-cell function and insulin sensitivity. Conclusions The DREAM study will comprehensively assess the metabolic and endocrine changes that precede and lead to the development of DM after AP.",

keywords = "AIRg - acute insulin response to glucose, AP - acute pancreatitis, AUC - area under the curve, DM - diabetes mellitus, DREAM - Diabetes Related to Acute Pancreatitis and its Mechanisms, FSIGTT - frequently sampled intravenous glucose tolerance test, GIP - glucose-dependent insulinotropic polypeptide, GLP-1 - glucagon-like peptide 1, HOMA-IR - homeostasis model assessment-insulin resistance, MMTT - mixed meal tolerance test, OGTT - oral glucose tolerance test, PP - pancreatic polypeptide, frequently sampled intravenous glucose tolerance test, islet, mixed-meal tolerance test, pancreatogenic diabetes, type 3c diabetes mellitus, β-cell function",

author = "{Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)} and Dungan, {Kathleen M.} and Hart, {Phil A.} and Andersen, {Dana K.} and Marina Basina and Chinchilli, {Vernon M.} and Danielson, {Kirstie K.} and Carmella Evans-Molina and Goodarzi, {Mark O.} and Greenbaum, {Carla J.} and Kalyani, {Rita R.} and Laughlin, {Maren R.} and Ariana Pichardo-Lowden and Pratley, {Richard E.} and Jose Serrano and Sims, {Emily K.} and Cate Speake and Dhiraj Yadav and Bellin, {Melena D.} and Toledo, {Frederico G.S.}",

note = "Funding Information: K.M.D. has declared research support from Sanofi, Viacyte, Abbott, and Dexcom; consulting activities with Eli Lilly, Boehringer Ingelheim, Elsevier, and Dexcom; and honoraria from UptoDate, Medscape, Academy for Continued Healthcare Learning, and Cardiometabolic Health Congress. M.D.B. has declared research support from Viacyte and Dexcom and consulting activities with Insulet (advisory board). C.E.-M. has received research support from Lilly, Astellas Pharma, Bristol Myers Squibb, and Nimbus Therapeutics and consulting/advisory fees from Avotres, Inc, DiogenX, Isla Technologies, Provention Bio, Inc, MaiCell Therapeutics, and Dompe. R.E.P. has received grants (directed to his institution) from Hanmi Pharmaceutical Co, Ltd, Janssen, Metavention, Novo Nordisk, Poxel SA, and Sanofi; has received consulting fees (directed to his institution) from AstraZeneca, Corcept Therapeutics Incorporated, Glytec LLC, Hanmi Pharmaceutical Co, Ltd, Janssen, Merck & Co, Inc., Mundipharma, Novo Nordisk, Pfizer, Inc, Sanofi, Scohia Pharma, Inc, and Sun Pharmaceutical Industries; and has received support for attending meetings/travel (directed to his institution or to the travel provider) from AstraZeneca, Glytec LLC, Merck & Co, Inc, Mundipharma, Novo Nordisk, and Pfizer, Inc. E.K.S. has received honoraria from Medscape. C.S. has participated on an advisory board for Vertex Pharmaceuticals. F.G.S.T. has declared research support from Domp{\'e} Pharmaceuticals and previous consulting activities with Sanofi, Eli Lilly, and AstraZeneca. The other authors declare no conflict of interest. Funding Information: The T1DAP Consortium is funded by the National Institute of Diabetes and Digestive and Kidney Diseases: grants U01DK127384, U01DK127367, U01DK127377, U01DK127392, U01DK127382, U01DK127403, U01DK127404, U01DK127388, U01DK127395, U01DK127378, and U01DK127400. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} Wolters Kluwer Health, Inc. All rights reserved.",

year = "2022",

month = jul,

day = "1",

doi = "10.1097/mpa.0000000000002074",

language = "English (US)",

volume = "51",

pages = "575--579",

journal = "Pancreas",

issn = "0885-3177",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Assessing the Pathophysiology of Hyperglycemia in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study

T2 - From the Type 1 Diabetes in Acute Pancreatitis Consortium

AU - Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)

AU - Dungan, Kathleen M.

AU - Hart, Phil A.

AU - Andersen, Dana K.

AU - Basina, Marina

AU - Chinchilli, Vernon M.

AU - Danielson, Kirstie K.

AU - Evans-Molina, Carmella

AU - Goodarzi, Mark O.

AU - Greenbaum, Carla J.

AU - Kalyani, Rita R.

AU - Laughlin, Maren R.

AU - Pichardo-Lowden, Ariana

AU - Pratley, Richard E.

AU - Serrano, Jose

AU - Sims, Emily K.

AU - Speake, Cate

AU - Yadav, Dhiraj

AU - Bellin, Melena D.

AU - Toledo, Frederico G.S.

N1 - Funding Information: K.M.D. has declared research support from Sanofi, Viacyte, Abbott, and Dexcom; consulting activities with Eli Lilly, Boehringer Ingelheim, Elsevier, and Dexcom; and honoraria from UptoDate, Medscape, Academy for Continued Healthcare Learning, and Cardiometabolic Health Congress. M.D.B. has declared research support from Viacyte and Dexcom and consulting activities with Insulet (advisory board). C.E.-M. has received research support from Lilly, Astellas Pharma, Bristol Myers Squibb, and Nimbus Therapeutics and consulting/advisory fees from Avotres, Inc, DiogenX, Isla Technologies, Provention Bio, Inc, MaiCell Therapeutics, and Dompe. R.E.P. has received grants (directed to his institution) from Hanmi Pharmaceutical Co, Ltd, Janssen, Metavention, Novo Nordisk, Poxel SA, and Sanofi; has received consulting fees (directed to his institution) from AstraZeneca, Corcept Therapeutics Incorporated, Glytec LLC, Hanmi Pharmaceutical Co, Ltd, Janssen, Merck & Co, Inc., Mundipharma, Novo Nordisk, Pfizer, Inc, Sanofi, Scohia Pharma, Inc, and Sun Pharmaceutical Industries; and has received support for attending meetings/travel (directed to his institution or to the travel provider) from AstraZeneca, Glytec LLC, Merck & Co, Inc, Mundipharma, Novo Nordisk, and Pfizer, Inc. E.K.S. has received honoraria from Medscape. C.S. has participated on an advisory board for Vertex Pharmaceuticals. F.G.S.T. has declared research support from Dompé Pharmaceuticals and previous consulting activities with Sanofi, Eli Lilly, and AstraZeneca. The other authors declare no conflict of interest. Funding Information: The T1DAP Consortium is funded by the National Institute of Diabetes and Digestive and Kidney Diseases: grants U01DK127384, U01DK127367, U01DK127377, U01DK127392, U01DK127382, U01DK127403, U01DK127404, U01DK127388, U01DK127395, U01DK127378, and U01DK127400. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © Wolters Kluwer Health, Inc. All rights reserved.

PY - 2022/7/1

Y1 - 2022/7/1

N2 - Objectives The metabolic abnormalities that lead to diabetes mellitus (DM) after an episode of acute pancreatitis (AP) have not been extensively studied. This article describes the objectives, hypotheses, and methods of mechanistic studies of glucose metabolism that comprise secondary outcomes of the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study. Methods Three months after an index episode of AP, participants without preexisting DM will undergo baseline testing with an oral glucose tolerance test. Participants will be followed longitudinally in three subcohorts with distinct metabolic tests. In the first and largest subcohort, oral glucose tolerance tests will be repeated 12 months after AP and annually to assess changes in β-cell function, insulin secretion, and insulin sensitivity. In the second, mixed meal tolerance tests will be performed at 3 and 12 months, then annually, and following incident DM to assess incretin and pancreatic polypeptide responses. In the third, frequently sampled intravenous glucose tolerance tests will be performed at 3 months and 12 months to assess the first-phase insulin response and more precisely measure β-cell function and insulin sensitivity. Conclusions The DREAM study will comprehensively assess the metabolic and endocrine changes that precede and lead to the development of DM after AP.

AB - Objectives The metabolic abnormalities that lead to diabetes mellitus (DM) after an episode of acute pancreatitis (AP) have not been extensively studied. This article describes the objectives, hypotheses, and methods of mechanistic studies of glucose metabolism that comprise secondary outcomes of the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study. Methods Three months after an index episode of AP, participants without preexisting DM will undergo baseline testing with an oral glucose tolerance test. Participants will be followed longitudinally in three subcohorts with distinct metabolic tests. In the first and largest subcohort, oral glucose tolerance tests will be repeated 12 months after AP and annually to assess changes in β-cell function, insulin secretion, and insulin sensitivity. In the second, mixed meal tolerance tests will be performed at 3 and 12 months, then annually, and following incident DM to assess incretin and pancreatic polypeptide responses. In the third, frequently sampled intravenous glucose tolerance tests will be performed at 3 months and 12 months to assess the first-phase insulin response and more precisely measure β-cell function and insulin sensitivity. Conclusions The DREAM study will comprehensively assess the metabolic and endocrine changes that precede and lead to the development of DM after AP.

KW - AIRg - acute insulin response to glucose

KW - AP - acute pancreatitis

KW - AUC - area under the curve

KW - DM - diabetes mellitus

KW - DREAM - Diabetes Related to Acute Pancreatitis and its Mechanisms

KW - FSIGTT - frequently sampled intravenous glucose tolerance test

KW - GIP - glucose-dependent insulinotropic polypeptide

KW - GLP-1 - glucagon-like peptide 1

KW - HOMA-IR - homeostasis model assessment-insulin resistance

KW - MMTT - mixed meal tolerance test

KW - OGTT - oral glucose tolerance test

KW - PP - pancreatic polypeptide

KW - frequently sampled intravenous glucose tolerance test

KW - islet

KW - mixed-meal tolerance test

KW - pancreatogenic diabetes

KW - type 3c diabetes mellitus

KW - β-cell function

UR - http://www.scopus.com/inward/record.url?scp=85139571728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139571728&partnerID=8YFLogxK

U2 - 10.1097/mpa.0000000000002074

DO - 10.1097/mpa.0000000000002074

M3 - Article

C2 - 36206461

AN - SCOPUS:85139571728

SN - 0885-3177

VL - 51

SP - 575

EP - 579

JO - Pancreas

JF - Pancreas

IS - 6

ER -

Assessing the Pathophysiology of Hyperglycemia in the D iabetes RE lated to A cute Pancreatitis and Its M echanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this